论文部分内容阅读
目的观察低分子肝素治疗不稳定型心绞痛的临床疗效及安全性。方法于2005年11月至2006年8月对102例不稳定心绞痛患者随机分为低分子肝素组和普通肝素组。观察两组心绞痛、心电图改善情况、不良反应及住院期间心血管事件发生率;比较两组血小板计数(PIT),凝血酶原时间(PT),部分凝血活酶时间(APTT)及肝肾功能变化。结果两组治疗后心绞痛、心电图均明显改善,住院期间心血管事件发生率低,低分子肝素组不良反应发生率明显低于普通肝素组,两组治疗前后 PIT、APTT、PT、肝肾功能未见明显改变。结论低分子肝素治疗不稳定型心绞痛疗效好、安全、简便。
Objective To observe the clinical efficacy and safety of low molecular weight heparin in the treatment of unstable angina pectoris. Methods From November 2005 to August 2006, 102 patients with unstable angina were randomly divided into low molecular weight heparin group and unfractionated heparin group. The changes of angina pectoris, electrocardiogram, adverse reactions and incidence of cardiovascular events during hospital stay were observed. The changes of platelet count (PIT), prothrombin time (PT), partial thromboplastin time (APTT) . Results The angina pectoris and electrocardiogram were significantly improved after treatment in both groups. The incidence of cardiovascular events during hospitalization was low. The incidence of adverse reactions in LMWH group was significantly lower than that in unfractionated heparin group. PIT, APTT, PT, See obvious change. Conclusion Low molecular weight heparin is effective and safe in treating unstable angina pectoris.